Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

2(66.7%)

N/A

1(33.3%)

3Total

Phase 4(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07397845Not ApplicableNot Yet Recruiting

Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial

Role: lead

NCT06420505Recruiting

Evaluation of the Vivo Isar Stent System in Routine Clinical Practice

Role: lead

NCT03918070Active Not Recruiting

Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems

Role: lead

NCT05703646Recruiting

Safety and Clinical Performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Stents in Routine Practice

Role: lead

NCT00152308Phase 4Terminated

Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis

Role: lead

NCT00368953Phase 4Completed

YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus

Role: collaborator

All 6 trials loaded